SCHEMBL6481983

SCHEMBL6481983

Clc1ccc2c(c1Nc1ncnc3cccc(ON4CCCCC4)c13)OCO2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 20/20 0.67
KDR P35968 11/20 0.54
CSK P41240 4/20 0.52
EPHB4 P54760 2/20 0.52
TEK Q02763 2/20 0.52
EGFR P00533 2/20 0.51
LCK P06239 2/20 0.51
YES1 P07947 2/20 0.51
FGFR1 P11362 1/20 0.51
AURKB Q96GD4 1/20 0.51
BMPR1B O00238 1/20 0.47
GAK O14976 1/20 0.47
EPHB6 O15197 1/20 0.47
RIPK2 O43353 1/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
FYN P06241 1/20 0.47
LYN P07948 1/20 0.47
RET P07949 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3279959 0.81 SRC (0.84) SRCKDRCSKEPHB4EGFR
SCHEMBL3275761 0.80 SRC (1.00) SRCKDRCSKEPHB4TEK
SCHEMBL3278858 0.79 SRC (0.66) SRCKDRCSKEPHB4TEK
SCHEMBL18533999 0.79 SRC (0.79) SRCKDRCSKEPHB4EGFR
Hydrochloric Acid SCHEMBL3280091 0.78 SRC (0.98) SRCKDRCSKEPHB4TEK
Hydrochloric Acid SCHEMBL3283164 0.78 SRC (0.65) SRCKDRCSKEPHB4TEK
SCHEMBL3195521 0.78 SRC (0.78) SRCKDRCSKEPHB4EGFR
Hydrochloric Acid SCHEMBL3276006 0.78 SRC (0.77) SRCKDRCSKEPHB4EGFR
Hydrochloric Acid SCHEMBL3281883 0.76 SRC (0.78) SRCKDRCSKEPHB4TEK
Hydrochloric Acid SCHEMBL6736242 0.75 SRC (0.63) SRCKDRCSKEPHB4TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038050-A1 Quinazoline derivatives for the treatment of t cell mediated diseases ASTRAZENECA AB (SE) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038050-A1 Quinazoline derivatives for the treatment of t cell mediated diseases CD4, HLA-DRB1, IFNG SRC 3241/4885KDR 4015/4885CSK 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.